

Estela Jacinto

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1013816/publications.pdf>

Version: 2024-02-01

28
papers

6,660
citations

535685

17
h-index

685536

24
g-index

29
all docs

29
docs citations

29
times ranked

10370
citing authors

#	ARTICLE	IF	CITATIONS
1	MTOR Signaling and Metabolism in Early T Cell Development. <i>Genes</i> , 2021, 12, 728.	1.0	16
2	Regulation and metabolic functions of mTORC1 and mTORC2. <i>Physiological Reviews</i> , 2021, 101, 1371-1426.	13.1	250
3	Rapalink-1 Increased Infarct Size in Early Cerebral Ischemiaâ€“Reperfusion With Increased Bloodâ€“Brain Barrier Disruption. <i>Frontiers in Physiology</i> , 2021, 12, 706528.	1.3	8
4	Inhibition of serum and glucocorticoid regulated kinases by GSK650394 reduced infarct size in early cerebral ischemia-reperfusion with decreased BBB disruption. <i>Neuroscience Letters</i> , 2021, 762, 136143.	1.0	8
5	KPT-9274, an Inhibitor of PAK4 and NAMPT, Leads to Downregulation of mTORC2 in Triple Negative Breast Cancer Cells. <i>Chemical Research in Toxicology</i> , 2020, 33, 482-491.	1.7	21
6	Lysophosphatidic acid increased infarct size in the early stage of cerebral ischemia-reperfusion with increased BBB permeability. <i>Journal of Stroke and Cerebrovascular Diseases</i> , 2020, 29, 105029.	0.7	6
7	mTORC2 Is Involved in the Induction of RSK Phosphorylation by Serum or Nutrient Starvation. <i>Cells</i> , 2020, 9, 1567.	1.8	6
8	Dual-mTOR Inhibitor Rapalink-1 Reduces Prostate Cancer Patient-Derived Xenograft Growth and Alters Tumor Heterogeneity. <i>Frontiers in Oncology</i> , 2020, 10, 1012.	1.3	24
9	The young and the restless: Isolating the dynamic mammalian preribosomes. <i>Journal of Biological Chemistry</i> , 2019, 294, 10758-10759.	1.6	0
10	Amplifying mTORC2 signals through AMPK during energetic stress. <i>Science Signaling</i> , 2019, 12, .	1.6	9
11	Targeting mTOR and Metabolism in Cancer: Lessons and Innovations. <i>Cells</i> , 2019, 8, 1584.	1.8	149
12	Akt activation improves microregional oxygen supply/consumption balance after cerebral ischemia-reperfusion. <i>Brain Research</i> , 2018, 1683, 48-54.	1.1	17
13	mTORC2 modulates the amplitude and duration of GFAT1 Ser-243 phosphorylation to maintain flux through the hexosamine pathway during starvation. <i>Journal of Biological Chemistry</i> , 2018, 293, 16464-16478.	1.6	30
14	Protein kinase CÎ¶ exhibits constitutive phosphorylation and phosphatidylinositol-3,4,5-triphosphate-independent regulation. <i>Biochemical Journal</i> , 2016, 473, 509-523.	1.7	42
15	mTORC2 Responds to Glutamine Catabolite Levels to Modulate the Hexosamine Biosynthesis Enzyme GFAT1. <i>Molecular Cell</i> , 2016, 63, 811-826.	4.5	97
16	Mammalian Target of Rapamycin Complex 2 Modulates Î±Î²TCR Processing and Surface Expression during Thymocyte Development. <i>Journal of Immunology</i> , 2014, 193, 1162-1170.	0.4	22
17	mTOR Complex 2 Regulates Proper Turnover of Insulin Receptor Substrate-1 via the Ubiquitin Ligase Subunit Fbw8. <i>Molecular Cell</i> , 2012, 48, 875-887.	4.5	91
18	The Target of Rapamycin: Structure and Functions. , 2012, , .		4

#	ARTICLE	IF	CITATIONS
19	Mammalian TOR signaling to the AGC kinases. <i>Critical Reviews in Biochemistry and Molecular Biology</i> , 2011, 46, 527-547.	2.3	68
20	TFEBulous control of traffic by mTOR. <i>EMBO Journal</i> , 2011, 30, 3215-3216.	3.5	0
21	mTORC2 can associate with ribosomes to promote cotranslational phosphorylation and stability of nascent Akt polypeptide. <i>EMBO Journal</i> , 2010, 29, 3939-3951.	3.5	290
22	What controls TOR?. <i>IUBMB Life</i> , 2008, 60, 483-496.	1.5	36
23	The mammalian target of rapamycin complex 2 controls folding and stability of Akt and protein kinase C. <i>EMBO Journal</i> , 2008, 27, 1932-1943.	3.5	482
24	TOR regulation of AGC kinases in yeast and mammals. <i>Biochemical Journal</i> , 2008, 410, 19-37.	1.7	188
25	Phosphatase Targets in TOR Signaling. , 2007, 365, 323-334.		7
26	SIN1/MIP1 Maintains rictor-mTOR Complex Integrity and Regulates Akt Phosphorylation and Substrate Specificity. <i>Cell</i> , 2006, 127, 125-137.	13.5	1,231
27	Mammalian TOR complex 2 controls the actin cytoskeleton and is rapamycin insensitive. <i>Nature Cell Biology</i> , 2004, 6, 1122-1128.	4.6	1,873
28	Two TOR Complexes, Only One of which Is Rapamycin Sensitive, Have Distinct Roles in Cell Growth Control. <i>Molecular Cell</i> , 2002, 10, 457-468.	4.5	1,685